1,014
Views
9
CrossRef citations to date
0
Altmetric
Author's View

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

, & ORCID Icon
Article: e1358334 | Received 12 Jul 2017, Accepted 15 Jul 2017, Published online: 21 Aug 2017

References

  • Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014; 14:135-46. doi:10.1038/nrc3670. PMID:24457417
  • Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348:69-74. doi:10.1126/science.aaa4971. PMID:25838375
  • Kralovics R, Passamonti F, Buser AS, Teo S, Tiedt R, Ph D, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779-90. doi:10.1056/NEJMoa051113. PMID:15858187
  • Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369:2379-90. doi:10.1056/NEJMoa1311347. PMID:24325356
  • Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369:2391-405. doi:10.1056/NEJMoa1312542. PMID:24325359
  • Holmstrom MO, Hjortso MD, Ahmad SM, Met O, Martinenaite E, Riley C, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH. The JAK2V617F mutation is a target for specific T-cells in the JAK2V617F positive myeloproliferative neoplasms. Leukemia. 2017; 31:495-8. doi:10.1038/leu.2016.290. PMID:27761006
  • Holmstrom MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia. 2016; 30:2413-6. doi:10.1038/leu.2016.233. PMID:27560107
  • Holmstrom MO, Martinenaite E, Ahmad SM, Met O, Friese C, Kjaer L, Riley CH, thor Straten P, Svane IM, Hasselbalch HC et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia 2017; doi:10.1038/leu.2017.214
  • Andersen MH. Anti-regulatory T cells. Semin Immunopathol. 2017; 39:317-26. doi:10.1007/s00281-016-0593-x. PMID:27677755
  • Kiladjian J-J, Giraudier S, Cassinat B. Interferon-alpha for the therapy of myeloproliferative neoplasms: Targeting the malignant clone. Leukemia 2015; 30:1-6. doi:10.1038/leu.2015.326. PMID:26108693

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.